Latest news and press releases about Q32 Bio Inc. (QTTB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation.
Price
| Price | $10.98 |
| Market Cap | $327M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 3.84 |
| Price / Book | 1.42 |
| EV / EBITDA | 7.13 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 76.88% |
| Return on Invested Capital | 19.30% |
| Return on Assets | 29.16% |
| Gross Margin | 99.84% |
| Operating Margin | 39.94% |
| Net Margin | 62.87% |
Related companies: ANTX · BOLD · GBIO · INTS · ITRM · NXTC · PSTV
Explore sector: Healthcare · Biotechnology
More sections of QTTB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks